Related Experiment Videos

[Pancytopenia following non-A, non-B hepatitis]

T Lorenz¹, V Heinemann, U Jehn

¹Medizinische Klinik III, Klinikum Grosshadern, Ludwig-Maximilians-Universität München.

|August 1, 1992

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Growth differentiation factor-15 (GDF-15) in localized pancreatic adenocarcinoma treated with multiagent chemotherapy: a biomarker analysis from the NEOLAP trial (AIO-PAK-0113).

ESMO gastrointestinal oncology·2026

Risk of disease progression in first-line metastatic colorectal cancer therapy to guide disease reassessments-analysis of 11 trials by AIO and GONO.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Translating efficacy of liver transplantation in liver-limited metastatic colorectal cancer into clinical practice: the TransMet trial.

ESMO open·2024

Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI.

ESMO open·2024

Dermatology-related quality-of-life outcomes in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab (Pmab) maintenance after FOLFOX + Pmab induction: a prespecified secondary analysis of the phase II randomized PanaMa (AIO KRK 0212) trial.

ESMO open·2024

Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110).

ESMO open·2024

See all related articles